Khloris Biosciences Competitors and Similar CompaniesClear all
Khloris Biosciences's competitors and similar companies include Clovis Oncology, Takeda, Puma Biotechnology and Ablynx.
 Khloris Biosciences Khloris Biosciences is a biotechnology company developing the treatment of cardiovascular, oncology, and other diseases. |  Clovis Oncology Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents. |  Takeda Takeda Pharmaceutical (武田薬品工業株式会社) is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products. |  Puma Biotechnology Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer. |  Ablynx Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. | |
Founding Date | Founding Date 2017 | Founding Date 2009 | Founding Date 1781 | Founding Date 2010 | Founding Date 2001 |
Type | Type Private | Type Public | Type Public | Type Public | Type Subsidiary |
Tags | |||||
Locations | Locations Mountain View, US HQ | Locations Los Angeles, US HQ | Locations Gent, BE HQ | ||
Employees | Employees 1214% decrease | Employees 4843% increase | Employees 47,4554% decrease | Employees 27214% decrease | Employees 1274% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) 10.6 m | Valuation ($) 43.7 b | Valuation ($) 136.8 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $148.8m (FY, 2021) | Revenue (est.) ¥4.6t (FY, 2025) | Revenue (est.) $230.5m (FY, 2024) | Revenue (est.) €85.2m (FY, 2016) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods ¥818.8b (FY, 2025) | Cost of goods $64.4m (FY, 2024) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit ¥3.8t (FY, 2025) | Gross profit $166.1m (FY, 2024) | Gross profit N/A |
Net income | Net income N/A | Net income ($264.5m) (FY, 2021) | Net income ¥108.1b (FY, 2025) | Net income $30.3m (FY, 2024) | Net income (€1.1m) (FY, 2016) |
Funding | |||||
Total funding raised | Total funding raised $ 5m | Total funding raised $ 357m | Total funding raised $ 57.8m | Total funding raised $ 172m | Total funding raised $ 498.8m |
For sources of this data, please see the company profile
View Company Profiles
Clovis Oncology
HQ
Boulder, US
Employees
484↑ 3% increase
Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents.
View companyTakeda
HQ
Tokyo, JP
Employees
47,455↓ 4% decrease
Takeda Pharmaceutical (武田薬品工業株式会社) is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products.
View companyPuma Biotechnology
HQ
Los Angeles, US
Employees
272↓ 14% decrease
Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer.
View companyAblynx
HQ
Gent, BE
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments.
View company